BSE · 531592
Genpharmasec Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹45 Cr with net profit ₹2 Cr — a 3.51% net margin, versus 4.49% the period before.
Shareholding
As of 2026-06-30
- Promoter29.98%
- Public70.02%
1,01,134 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.87× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Trading · ranked #244 of 674 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Enterprises Limited | ₹4,14,150 Cr | 160.88 | 4.37 | 3.93% | 6.78% |
| Avenue Supermarts Limited | ₹2,40,548 Cr | 78.65 | 9.83 | 12.14% | 4.29% |
| Trent Ltd. | ₹1,49,433 Cr | 81.73 | 21.39 | 24.62% | 8.64% |
| FSN E-Commerce Ventures Ltd. | ₹98,675 Cr | 370.43 | 68.63 | 13.87% | 2.41% |
| Vishal Mega Mart Limited | ₹47,649 Cr | 53.53 | 6.42 | 11.32% | 6.61% |
| Aegis Logistics Limited | ₹47,511 Cr | 37.97 | 7.85 | 14.83% | 13.95% |
| Aditya Infotech Limited | ₹45,256 Cr | 94.83 | 24.11 | 19.61% | 9.77% |
| Premier Energies Limited | ₹44,224 Cr | 26.56 | 10.27 | 35.05% | 19.67% |
| Redington Limited | ₹30,778 Cr | 17.11 | 3.03 | 14.67% | 1.33% |
| Honasa Consumer Limited | ₹15,361 Cr | 60.87 | 10.87 | 14.16% | 9.75% |
| Genpharmasec Limited(this company) | ₹65 Cr | 34.33 | 0.98 | 2.42% | -14.64% |
AI analysis
AI-generated · google/gemini-2.5-flashGenpharmasec Limited does not have specified business activities. The company reported a market capitalization of Rs 58 Cr. Its revenue stood at Rs 36.78 Cr with a profit margin of 31.4%.
Positives
- +The company has a low debt-to-equity ratio of 0.07.
- +The Return on Equity (ROE) is significantly high at 242%.
- +The company recorded a profit margin of 31.4%.
Negatives
- −Promoter holding is relatively low at 29.9792%.
- −Return on Capital Employed (ROCE) is low at 2.1844%.
- −The company experienced negative net profit in December 2025 (-Rs 0.83 Cr) and September 2025 (-Rs 1.18 Cr).
Financial Performance
For the fiscal year ending March 2025, Genpharmasec Limited reported revenue of Rs 36.784 Cr and a net profit of Rs 1.2312 Cr. Quarterly revenue for March 2026 was Rs 55.43 Cr, with a net profit of Rs 1.23 Cr. Over the past four quarters, revenue fluctuated, with a high of Rs 55.43 Cr in March 2026 and a low of Rs 8.48 Cr in December 2024.
Profitability & Returns
Genpharmasec Limited achieved a profit margin of 31.4%. The company's Return on Capital Employed (ROCE) was 2.1844% and Return on Equity (ROE) was 242%. Earnings per share (EPS) for the fiscal year ending March 2025 was Rs 0.02. The PE ratio for the company is 35.
Balance Sheet
The company's debt-to-equity ratio is 0.07, indicating a low level of debt relative to its equity. The book value per share is Rs 1.2.
Ownership & Pledges
As of June 30, 2026, promoter holding in Genpharmasec Limited stood at 29.9792%, while public shareholding was 70.0208%. There is no pledged promoter holding. The number of shareholders was 101,134.
Regulatory & Surveillance
There is no information available regarding any surveillance measures on Genpharmasec Limited.
Data as of — price: 2026-09-11 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.